Biogen Inc. (NASDAQ:BIIB – Get Free Report) traded down 6.8% during trading on Wednesday after Bank Of America (Bofa) lowered ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Goldman Sachs lowered the firm’s price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...